JP5363655B2 - アンチセンス核酸 - Google Patents

アンチセンス核酸 Download PDF

Info

Publication number
JP5363655B2
JP5363655B2 JP2012531987A JP2012531987A JP5363655B2 JP 5363655 B2 JP5363655 B2 JP 5363655B2 JP 2012531987 A JP2012531987 A JP 2012531987A JP 2012531987 A JP2012531987 A JP 2012531987A JP 5363655 B2 JP5363655 B2 JP 5363655B2
Authority
JP
Japan
Prior art keywords
nucleic acid
exon
synthetic nucleic
antisense oligomer
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012531987A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012029986A1 (ja
Inventor
直樹 渡辺
洋平 佐藤
伸一 武田
哲也 永田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
National Center of Neurology and Psychiatry
Original Assignee
Nippon Shinyaku Co Ltd
National Center of Neurology and Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5363655(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd, National Center of Neurology and Psychiatry filed Critical Nippon Shinyaku Co Ltd
Priority to JP2012531987A priority Critical patent/JP5363655B2/ja
Publication of JPWO2012029986A1 publication Critical patent/JPWO2012029986A1/ja
Application granted granted Critical
Publication of JP5363655B2 publication Critical patent/JP5363655B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012531987A 2010-09-01 2011-08-31 アンチセンス核酸 Active JP5363655B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012531987A JP5363655B2 (ja) 2010-09-01 2011-08-31 アンチセンス核酸

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010196032 2010-09-01
JP2010196032 2010-09-01
PCT/JP2011/070318 WO2012029986A1 (ja) 2010-09-01 2011-08-31 アンチセンス核酸
JP2012531987A JP5363655B2 (ja) 2010-09-01 2011-08-31 アンチセンス核酸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013184193A Division JP6141728B2 (ja) 2010-09-01 2013-09-05 アンチセンス核酸

Publications (2)

Publication Number Publication Date
JPWO2012029986A1 JPWO2012029986A1 (ja) 2013-10-31
JP5363655B2 true JP5363655B2 (ja) 2013-12-11

Family

ID=45773054

Family Applications (12)

Application Number Title Priority Date Filing Date
JP2012531987A Active JP5363655B2 (ja) 2010-09-01 2011-08-31 アンチセンス核酸
JP2013184193A Active JP6141728B2 (ja) 2010-09-01 2013-09-05 アンチセンス核酸
JP2015256962A Active JP6193343B2 (ja) 2010-09-01 2015-12-28 アンチセンス核酸
JP2017154320A Active JP6465932B2 (ja) 2010-09-01 2017-08-09 アンチセンス核酸
JP2019001091A Active JP6647430B2 (ja) 2010-09-01 2019-01-08 アンチセンス核酸
JP2020003338A Active JP6867619B2 (ja) 2010-09-01 2020-01-14 アンチセンス核酸
JP2021008200A Active JP6867620B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021008201A Active JP6867621B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021008202A Active JP6867636B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021058526A Pending JP2021104037A (ja) 2010-09-01 2021-03-30 アンチセンス核酸
JP2022209270A Pending JP2023036865A (ja) 2010-09-01 2022-12-27 アンチセンス核酸
JP2024145055A Pending JP2024170458A (ja) 2010-09-01 2024-08-27 アンチセンス核酸

Family Applications After (11)

Application Number Title Priority Date Filing Date
JP2013184193A Active JP6141728B2 (ja) 2010-09-01 2013-09-05 アンチセンス核酸
JP2015256962A Active JP6193343B2 (ja) 2010-09-01 2015-12-28 アンチセンス核酸
JP2017154320A Active JP6465932B2 (ja) 2010-09-01 2017-08-09 アンチセンス核酸
JP2019001091A Active JP6647430B2 (ja) 2010-09-01 2019-01-08 アンチセンス核酸
JP2020003338A Active JP6867619B2 (ja) 2010-09-01 2020-01-14 アンチセンス核酸
JP2021008200A Active JP6867620B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021008201A Active JP6867621B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021008202A Active JP6867636B1 (ja) 2010-09-01 2021-01-21 アンチセンス核酸
JP2021058526A Pending JP2021104037A (ja) 2010-09-01 2021-03-30 アンチセンス核酸
JP2022209270A Pending JP2023036865A (ja) 2010-09-01 2022-12-27 アンチセンス核酸
JP2024145055A Pending JP2024170458A (ja) 2010-09-01 2024-08-27 アンチセンス核酸

Country Status (20)

Country Link
US (16) US9079934B2 (cg-RX-API-DMAC7.html)
EP (6) EP3018211B1 (cg-RX-API-DMAC7.html)
JP (12) JP5363655B2 (cg-RX-API-DMAC7.html)
KR (1) KR101310569B1 (cg-RX-API-DMAC7.html)
CN (1) CN103154245B (cg-RX-API-DMAC7.html)
AU (1) AU2011296882B2 (cg-RX-API-DMAC7.html)
CA (1) CA2809637C (cg-RX-API-DMAC7.html)
CY (2) CY1117367T1 (cg-RX-API-DMAC7.html)
DK (2) DK2612917T3 (cg-RX-API-DMAC7.html)
ES (2) ES2567411T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20160336T1 (cg-RX-API-DMAC7.html)
HU (2) HUE027321T2 (cg-RX-API-DMAC7.html)
LT (1) LT3018211T (cg-RX-API-DMAC7.html)
PL (2) PL3018211T3 (cg-RX-API-DMAC7.html)
PT (1) PT3018211T (cg-RX-API-DMAC7.html)
RS (2) RS54649B1 (cg-RX-API-DMAC7.html)
SI (2) SI2612917T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201900559T1 (cg-RX-API-DMAC7.html)
TW (1) TWI541024B (cg-RX-API-DMAC7.html)
WO (1) WO2012029986A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182517A1 (ja) 2020-03-11 2021-09-16 隆光 矢野 －１フレームシフトを誘導するための１本鎖核酸分子及び組成物

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206781B1 (en) * 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
EP2762567B1 (en) 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
PL2499249T3 (pl) 2009-11-12 2019-03-29 Univ Western Australia Cząsteczki antysensowne i sposoby leczenia patologii
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
WO2014100714A1 (en) * 2012-12-20 2014-06-26 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
NZ631132A (en) * 2013-03-14 2017-06-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
BR122020016865B1 (pt) 2013-03-14 2022-12-27 Sarepta Therapeutics, Inc. Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
BR112015022998A2 (pt) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
RS58573B1 (sr) 2014-03-12 2019-05-31 Nippon Shinyaku Co Ltd Antisensna nukleinska kiselina
DK3146970T3 (da) * 2014-05-19 2022-12-05 Knc Laboratories Co Ltd Nukleinsyrelægemiddel til induktion af overspringning af en exonvariant af CD44-genet og øgning af ekspression af CD44-mRNA af normal type
TWI666317B (zh) * 2014-06-17 2019-07-21 Nippon Shinyaku Co., Ltd. 反義核酸
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
KR102473431B1 (ko) * 2015-09-15 2022-12-01 니뽄 신야쿠 가부시키가이샤 안티센스 핵산
US10563199B2 (en) * 2015-09-16 2020-02-18 Nippon Shinyaku Co., Ltd. Antisense nucleic acid for treating amyotrophy
CN114533900A (zh) 2015-10-09 2022-05-27 波涛生命科学有限公司 寡核苷酸组合物及其方法
BR112018007066A2 (pt) 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
FR3044926B1 (fr) 2015-12-09 2020-01-31 Genethon Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
KR101686379B1 (ko) 2016-02-05 2016-12-13 박정열 휴대용 구이기
PT3464306T (pt) * 2016-05-24 2024-05-17 Sarepta Therapeutics Inc Processos para preparar oligómeros morfolino de fosforodiamidato
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
AU2017270975B2 (en) 2016-05-24 2021-04-15 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
DK3464305T3 (da) 2016-05-24 2024-10-28 Sarepta Therapeutics Inc Fremgangsmåder til fremstilling af oligomerer
CN109152792B (zh) * 2016-06-30 2021-09-14 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
SG11201810143PA (en) 2016-06-30 2019-01-30 Sarepta Therapeutics Inc Exon skipping oligomers for muscular dystrophy
AU2017291960B2 (en) * 2016-07-05 2024-03-14 Biomarin Technologies B.V. Pre-mRNA splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
KR101715572B1 (ko) 2016-10-11 2017-03-22 박종찬 구이대 승강구조를 갖는 양방향 구이기
SMT202200366T1 (it) * 2016-12-19 2022-11-18 Sarepta Therapeutics Inc Coniugati di oligomeri per salto di esone per distrofia muscolare
PL3554552T3 (pl) 2016-12-19 2022-11-21 Sarepta Therapeutics, Inc. Koniugaty oligomerów do pomijania egzonów dla dystrofii mięśniowej
MY205600A (en) 2016-12-19 2024-10-29 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
CN120884604A (zh) 2017-06-02 2025-11-04 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
US20230038956A1 (en) * 2017-08-31 2023-02-09 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EP3687519A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2021521794A (ja) * 2018-04-26 2021-08-30 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
TWI844541B (zh) * 2018-05-11 2024-06-11 新加坡商波濤生命科學有限公司 寡核苷酸組成物及其使用方法
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
AU2019293687B2 (en) * 2018-06-26 2025-10-02 Nippon Shinyaku Co., Ltd. Composition comprising antisense oligonucleotide and use thereof for treatment of Duchenne muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EA202190416A1 (ru) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
BR112021010982A2 (pt) 2018-12-07 2021-08-31 Oxford University Innovation Limited Ligantes
US20220144902A1 (en) * 2018-12-25 2022-05-12 National Center Of Neurology And Psychiatry Method for inducing muscular cells using cells in spot urine
GB201821269D0 (en) * 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
CA3165961A1 (en) 2019-12-26 2021-07-01 Nippon Shinyaku Co., Ltd. Antisense nucleic acid that induces skipping of exon 50
CA3173049A1 (en) 2020-02-28 2021-09-02 Nippon Shinyaku Co., Ltd. Antisense nucleic acid inducing skipping of exon 51
CN116249454A (zh) * 2020-09-18 2023-06-09 天野酶制品株式会社 一种加工鹰嘴豆浆的制造方法
CA3211038A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
WO2022232478A1 (en) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4389893A4 (en) 2021-08-21 2025-09-10 Takeda Pharmaceuticals Co PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR
US20240366775A1 (en) 2021-08-24 2024-11-07 Peptidream Inc. Human transferrin receptor binding antibody-peptide conjugate
WO2023127918A1 (ja) 2021-12-27 2023-07-06 日本新薬株式会社 オリゴ核酸化合物の製造方法
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
EP4486386A1 (en) 2022-03-03 2025-01-08 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
JP2025079347A (ja) * 2022-03-11 2025-05-22 日本新薬株式会社 キャリアペプチドが連結された核酸
US20250195667A1 (en) 2022-03-17 2025-06-19 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2023214512A1 (ja) 2022-05-06 2023-11-09 学校法人常翔学園 人工ｒｎａ分子
WO2025153061A1 (zh) * 2024-01-19 2025-07-24 云合智药（苏州）生物科技有限公司 用于抑制激活素iib型受体基因表达的核酸及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002010790A (ja) * 2000-04-26 2002-01-15 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
WO2008036127A2 (en) * 2006-05-10 2008-03-27 Avi Biopharma, Inc. Oligonucleotide analogs having cationic intersubunit linkages
WO2010048586A1 (en) * 2008-10-24 2010-04-29 Avi Biopharma, Inc. Multiple exon skipping compositions for dmd
US20100168212A1 (en) * 2008-09-11 2010-07-01 Royal Holloway, University Of London Oligomers
WO2011057350A1 (en) * 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033986T2 (de) 1989-12-20 2003-03-13 Antivirals Inc., Portland Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体，デバイス及び医薬組成物
US7321828B2 (en) 1998-04-13 2008-01-22 Isis Pharmaceuticals, Inc. System of components for preparing oligonucleotides
JP2000325085A (ja) 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
JP4836366B2 (ja) 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
EP2386636B1 (en) 2002-11-25 2016-01-27 Masafumi Matsuo Ena nucleic acid drugs modifying splicing in mrna precursor
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
JP2006038608A (ja) 2004-07-27 2006-02-09 Tokyo Electric Power Co Inc:The 超音波検査装置及び方法
US20110046200A1 (en) 2004-08-03 2011-02-24 Michael T Howard Use of antisense oligonucleotides to effect translation modulation
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
EP1811024A1 (en) 2004-10-05 2007-07-25 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna and medicinal composition
JP2006129594A (ja) 2004-10-28 2006-05-18 Hitachi Ltd 船舶用電気推進装置の制御方法及びその装置
NZ563206A (en) 2005-04-22 2009-09-25 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the binding or SR proteins and by interfering with secondary RNA structure
CA2609032A1 (en) 2005-05-30 2006-12-07 Nippon Shinyaku Co., Ltd. Method for producing a nucleic-acid-containing complex preparation
PT3308788T (pt) * 2005-06-23 2019-01-30 Cold Spring Harbor Laboratory Composições e métodos para a modulação do splicing de smn2
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
JP4816396B2 (ja) 2006-10-12 2011-11-16 富士ゼロックス株式会社 画像形成装置
US8466255B2 (en) 2007-02-05 2013-06-18 Nippon Shinyaku Co., Ltd. Polyethylene glycol derivative
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
EP2207779B1 (en) 2007-11-15 2014-04-09 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
PT2344637E (pt) 2008-10-27 2015-03-23 Academisch Ziekenhuis Leiden Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne
JP2010196032A (ja) 2009-01-29 2010-09-09 Fujifilm Corp 水不溶性色材の分散体及びこの製造方法、これを用いた記録液、インクセット、印画物、画像形成方法、及び画像形成装置
WO2010123369A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
AU2010262862C1 (en) * 2009-06-17 2020-04-30 Biogen Ma Inc. Compositions and methods for modulation of SMN2 splicing in a subject
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
KR20140052963A (ko) 2011-02-08 2014-05-07 더 샬롯테-맥클렌버그 하스피털 오쏘러티 디/비/에이 카롤리나스 헬스케어 시스템 안티센스 올리고뉴클레오티드
CN103619356B (zh) 2011-05-05 2017-09-12 萨勒普塔医疗公司 肽寡核苷酸缀合物
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
CA2877644A1 (en) 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
WO2014100714A1 (en) 2012-12-20 2014-06-26 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
BR122020016865B1 (pt) 2013-03-14 2022-12-27 Sarepta Therapeutics, Inc. Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
NZ631132A (en) 2013-03-14 2017-06-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
BR112015022998A2 (pt) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
US10112977B2 (en) 2014-06-23 2018-10-30 Toagosei Co., Ltd. Peptide for inducing multinucleation in cells, and use therefor
US11053494B2 (en) 2014-08-09 2021-07-06 Research Institute At Nationwide Children's Hospital Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene
BR112018006445A2 (pt) 2015-09-30 2018-12-11 Sarepta Therapeutics Inc métodos para tratar distrofia muscular
BR112018007066A2 (pt) 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
DK3464305T3 (da) 2016-05-24 2024-10-28 Sarepta Therapeutics Inc Fremgangsmåder til fremstilling af oligomerer
US20190275072A1 (en) 2016-05-24 2019-09-12 Sarepta Therapeutics, Inc. Pharmaceutical compositions comprising eteplirsen
AU2017270975B2 (en) 2016-05-24 2021-04-15 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
PT3464306T (pt) 2016-05-24 2024-05-17 Sarepta Therapeutics Inc Processos para preparar oligómeros morfolino de fosforodiamidato
SG11201810143PA (en) 2016-06-30 2019-01-30 Sarepta Therapeutics Inc Exon skipping oligomers for muscular dystrophy
CN109152792B (zh) 2016-06-30 2021-09-14 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
BR112019009953A2 (pt) 2016-11-16 2019-10-08 Academisch Ziekenhuis Leiden substâncias direcionadas a vários órgãos ou tecidos selecionados
SMT202200366T1 (it) 2016-12-19 2022-11-18 Sarepta Therapeutics Inc Coniugati di oligomeri per salto di esone per distrofia muscolare
PL3554552T3 (pl) 2016-12-19 2022-11-21 Sarepta Therapeutics, Inc. Koniugaty oligomerów do pomijania egzonów dla dystrofii mięśniowej
MY205600A (en) 2016-12-19 2024-10-29 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
US20230038956A1 (en) 2017-08-31 2023-02-09 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
EP3687547A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020536058A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを処置するための併用療法
EP3687519A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002010790A (ja) * 2000-04-26 2002-01-15 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
WO2008036127A2 (en) * 2006-05-10 2008-03-27 Avi Biopharma, Inc. Oligonucleotide analogs having cationic intersubunit linkages
US20100168212A1 (en) * 2008-09-11 2010-07-01 Royal Holloway, University Of London Oligomers
WO2010048586A1 (en) * 2008-10-24 2010-04-29 Avi Biopharma, Inc. Multiple exon skipping compositions for dmd
WO2011057350A1 (en) * 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011052124; ＰＯＰＰＬＥＷＥＬＬ，　Ｌ．Ｊ．　ｅｔ　ａｌ．: 'Ｄｅｓｉｇｎ　ｏｆ　ｐｈｏｓｐｈｏｒｏｄｉａｍｉｄａｔｅ　ｍｏｒｐｈｏｌｉｎｏ　ｏｌｉｇｏｍｅｒｓ　（ＰＭＯｓ）　ｆｏｒ　ｔｈｅ　ｉｎｄｕｃｔｉｏｎ　ｏｆ　ｅｘｏｎ　ｓｋｉｐｐｉｎｇ　ｏｆ　ｔｈｅ　ｈ' Ｍｏｌ．　Ｔｈｅｒ． Ｖｏｌ．１７　Ｎｏ．３, 2009, ｐ．５５４-５６１ *
JPN6011052126; ＰＯＰＰＬＥＷＥＬＬ，　Ｌ．Ｊ．　ｅｔ　ａｌ．: 'Ｃｏｍｐａｒａｔｉｖｅ　ａｎａｌｙｓｉｓ　ｏｆ　ａｎｔｉｓｅｎｓｅ　ｏｌｉｇｏｎｕｃｌｅｏｔｉｄｅ　ｓｅｑｕｅｎｃｅｓ　ｔａｒｇｅｔｉｎｇ　ｅｘｏｎ　５３　ｏｆ　ｔｈｅ　ｈｕｍａｎ　ＤＭＤ　ｇｅｎｅ：' Ｎｅｕｒｏｍｕｓｃｕｌ．　Ｄｉｓｏｒｄ． Ｖｏｌ．２０　Ｎｏ．２, 201002, ｐ．１０２-１１０ *
JPN6011052128; ＡＡＲＴＳＭＡ-ＲＵＳ，　Ａ．　ｅｔ　ａｌ．: 'Ｔａｒｇｅｔｅｄ　ｅｘｏｎ　ｓｋｉｐｐｉｎｇ　ａｓ　ａ　ｐｏｔｅｎｔｉａｌ　ｇｅｎｅ　ｃｏｒｒｅｃｔｉｏｎ　ｔｈｅｒａｐｙ　ｆｏｒ　Ｄｕｃｈｅｎｎｅ　ｍｕｓｃｕｌａｒ　ｄｙｓｔｒｏｐｈｙ．' Ｎｅｕｒｏｍｕｓｃｕｌ．　Ｄｉｓｏｒｄ． Ｖｏｌ．１２　Ｓｕｐｐｌｅｍｅｎｔ, 2002, ｐ．Ｓ７１-Ｓ７７ *
JPN6011052130; ＷＩＬＴＯＮ，　Ｓ．Ｄ．　ｅｔ　ａｌ．: 'Ｍｏｌ．　Ｔｈｅｒ．' Ａｎｔｉｓｅｎｓｅ　ｏｌｉｇｏｎｕｃｌｅｏｔｉｄｅ-ｉｎｄｕｃｅｄ　ｅｘｏｎ　ｓｋｉｐｐｉｎｇ　ａｃｒｏｓｓ　ｔｈｅ　ｈｕｍａｎ　ｄｙｓｔｒｏｐｈｉｎ　ｇｅｎｅ　ｔｒａｎｓｃｒｉｐｔ． Ｖｏｌ．１５　Ｎｏ．７, 2007, ｐ．１２８８-１２９６ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021182517A1 (ja) 2020-03-11 2021-09-16 隆光 矢野 －１フレームシフトを誘導するための１本鎖核酸分子及び組成物

Also Published As

Publication number Publication date
EP2612917A4 (en) 2014-12-31
US10385092B2 (en) 2019-08-20
JP6867620B1 (ja) 2021-04-28
US10683322B2 (en) 2020-06-16
RS54649B1 (sr) 2016-08-31
JP2014054250A (ja) 2014-03-27
CN103154245B (zh) 2016-06-01
AU2011296882A1 (en) 2013-04-18
CY1117367T1 (el) 2017-04-26
CN103154245A (zh) 2013-06-12
JP2019062913A (ja) 2019-04-25
EP3018211A1 (en) 2016-05-11
JP2021072820A (ja) 2021-05-13
US20150166995A1 (en) 2015-06-18
PL3018211T3 (pl) 2020-02-28
KR20130069762A (ko) 2013-06-26
EP2612917B1 (en) 2016-02-24
WO2012029986A1 (ja) 2012-03-08
HUE046364T2 (hu) 2020-02-28
JPWO2012029986A1 (ja) 2013-10-31
US10487106B2 (en) 2019-11-26
HRP20160336T1 (hr) 2016-04-22
JP6465932B2 (ja) 2019-02-06
JP6141728B2 (ja) 2017-06-07
US10329319B2 (en) 2019-06-25
KR101310569B1 (ko) 2013-09-23
TW201215408A (en) 2012-04-16
EP3581655A1 (en) 2019-12-18
US10407461B2 (en) 2019-09-10
US20170320903A1 (en) 2017-11-09
US20210198306A1 (en) 2021-07-01
US20230151050A1 (en) 2023-05-18
JP2023036865A (ja) 2023-03-14
EP2612917A1 (en) 2013-07-10
US10662217B2 (en) 2020-05-26
EP3543341A1 (en) 2019-09-25
JP2021104037A (ja) 2021-07-26
LT3018211T (lt) 2019-10-25
AU2011296882B2 (en) 2015-04-09
DK3018211T3 (da) 2019-10-14
PL2612917T3 (pl) 2016-07-29
CA2809637C (en) 2018-06-05
JP2018027083A (ja) 2018-02-22
US20210179659A1 (en) 2021-06-17
JP6193343B2 (ja) 2017-09-06
JP2024170458A (ja) 2024-12-10
US20190218244A1 (en) 2019-07-18
US20190211049A1 (en) 2019-07-11
TWI541024B (zh) 2016-07-11
US10647741B2 (en) 2020-05-12
EP4403632A3 (en) 2024-10-23
ES2567411T3 (es) 2016-04-22
HUE027321T2 (en) 2016-10-28
EP4400168A2 (en) 2024-07-17
US9708361B2 (en) 2017-07-18
HRP20191770T1 (hr) 2019-12-27
DK2612917T3 (en) 2016-04-18
JP2016104021A (ja) 2016-06-09
JP2021072821A (ja) 2021-05-13
RS59361B1 (sr) 2019-11-29
RU2567664C2 (ru) 2015-11-10
US20250042933A1 (en) 2025-02-06
JP6867619B2 (ja) 2021-04-28
US20190315796A1 (en) 2019-10-17
US20190211050A1 (en) 2019-07-11
US10870676B2 (en) 2020-12-22
US9079934B2 (en) 2015-07-14
ES2750748T3 (es) 2020-03-27
SI2612917T1 (sl) 2016-05-31
US20200115411A1 (en) 2020-04-16
US20200109162A1 (en) 2020-04-09
US20210284680A1 (en) 2021-09-16
SMT201900559T1 (it) 2019-11-13
JP2021072822A (ja) 2021-05-13
JP6867636B1 (ja) 2021-04-28
CY1122167T1 (el) 2020-11-25
CA2809637A1 (en) 2012-03-08
JP6647430B2 (ja) 2020-02-14
SMT201600111B (it) 2016-07-01
EP3018211B1 (en) 2019-08-07
EP4400168A3 (en) 2024-10-23
EP4403632A2 (en) 2024-07-24
US11028122B1 (en) 2021-06-08
PT3018211T (pt) 2019-10-28
JP2020072724A (ja) 2020-05-14
US20210340171A1 (en) 2021-11-04
US20130211062A1 (en) 2013-08-15
JP6867621B1 (ja) 2021-04-28
RU2013114396A (ru) 2014-10-10
SI3018211T1 (sl) 2019-11-29
US20200102343A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP6867621B1 (ja) アンチセンス核酸
JP6701139B2 (ja) アンチセンス核酸
JP6384845B2 (ja) アンチセンス核酸
EP3118311A1 (en) Antisense nucleic acid

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130905

R150 Certificate of patent or registration of utility model

Ref document number: 5363655

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250